Home > Insider Trading > Filing (0000899243-21-018111)

Filing Details

Accession Number:: 0000899243-21-018111
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-04 13:00:00
Reporting Period:: 2020-12-23

Accepted Time:: 2021-05-04 16:30:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785530	Werewolf Therapeutics Inc.	HOWL	Pharmaceutical Preparations (2834)	823523180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1808244	Alon Lazarus	C/O Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 Cambridge MA 02138		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-05-04	1,235,917	$0.00	1,235,917	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-05-04	410,717	$0.00	1,646,634	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-05-04	400,000	$16.00	2,046,634	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Acquisiton	2020-12-23	3,560,551	$0.92	410,717	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2021-04-30	23,200	$0.00	23,200	$16.00
Common Stock	Series A Preferred Stock	Disposition	2021-05-04	10,714,284	$0.00	1,235,917	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-05-04	3,560,551	$0.00	410,717	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,560,551		No	4	P	Indirect
23,200	2031-04-29	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The securities are held directly by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. The Reporting Person is the Biotech Investment Manager of the Fund and, as a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd., Mr. Arkin and the Reporting Person may be deemed to share voting and investment power with respect to the shares held by the Fund.
On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The option was granted on April 30, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter.